Immunoprecise Antibodies Ltd represents values of innovation, collaboration, and scientific excellence. As a leading provider of custom antibody services, their corporate philosophy revolves around delivering high-quality products and services to support the research and development efforts of their clients. With a focus on advancing antibody discovery and engineering, Immunoprecise Antibodies Ltd is dedicated to pushing the boundaries of therapeutic antibody development. By leveraging a diverse set of proprietary platforms and expertise, they strive to accelerate drug discovery and improve patient outcomes. As an industry leader, Immunoprecise Antibodies Ltd continuously strives to exceed customer expectations and make significant contributions to the field of antibody-based therapeutics.

Immunoprecise Antibodies Ltd is primarily present in various countries and regions worldwide. With a strong global presence, the company operates in key markets, including North America, Europe, and Asia. It has established strategic partnerships and collaborations across multiple countries, enabling it to serve a diverse range of clients and biopharmaceutical companies worldwide. Immunoprecise Antibodies Ltd's dedication to expanding its global reach strengthens its position as a leading provider of custom antibody products and services.

Immunoprecise Antibodies Ltd has achieved several significant milestones in its history. The company has successfully developed a diverse and robust portfolio of proprietary therapeutic antibodies. They have also established strategic collaborations with leading global biopharmaceutical companies and academic institutions, which have resulted in numerous research and development partnerships. Immunoprecise Antibodies Ltd has consistently demonstrated expertise in antibody discovery, engineering, and development, enabling them to provide cutting-edge solutions in the field of biotechnology. Additionally, the company has expanded its state-of-the-art facilities and acquired advanced technologies, further enhancing its capabilities and positioning itself as a trusted partner in the biopharmaceutical industry.

Immunoprecise Antibodies Ltd, founded in 2001, is a global provider of custom antibody discovery and development services. Headquartered in Victoria, Canada, the company specializes in supporting the research and development efforts of pharmaceutical, biotechnology, and academic organizations. With a team of highly skilled scientists, Immunoprecise Antibodies Ltd offers a comprehensive range of services including hybridoma development, antibody humanization, engineering, and in vitro expression. The company also leverages its cutting-edge technologies and collaborations to deliver high-quality therapeutic antibodies for the treatment of various diseases. Over the years, Immunoprecise Antibodies Ltd has established itself as a reliable partner in the biopharmaceutical industry, combining expertise, innovation, and dedication to advancing antibody therapies worldwide.

The main competitors of Immunoprecise Antibodies Ltd in the market include companies like Abcam plc, GenScript Biotech Corporation, and Xencor Inc. These companies are also involved in the development and production of antibodies and related products. However, Immunoprecise Antibodies Ltd distinguishes itself with its unique technology platform and an extensive catalog of high-quality antibody products and services. With a strong focus on innovation and customer satisfaction, Immunoprecise Antibodies Ltd continues to compete effectively in the highly competitive market.

Immunoprecise Antibodies Ltd is primarily active in the biotechnology and pharmaceutical industries.

The business model of Immunoprecise Antibodies Ltd revolves around providing custom antibody development and contract research services to the biopharmaceutical industry. The company offers a comprehensive range of innovative solutions for the discovery and development of therapeutic antibodies. With a focus on advanced technology platforms and comprehensive antibody expertise, Immunoprecise Antibodies Ltd collaborates with pharmaceutical and biotech companies to accelerate their therapeutic antibody discovery and development programs. By leveraging their deep knowledge and state-of-the-art facilities, Immunoprecise Antibodies Ltd aims to support the biopharmaceutical industry in developing novel treatments and improving healthcare outcomes.

Immunoprecise Antibodies KGV ir -1,74.

Immunoprecise Antibodies KUV ir 0,92.

AlleAktien kvalitātes vērtējums Immunoprecise Antibodies ir 5/10.

gaidāmā Immunoprecise Antibodies apgrozījums ir 24,84 milj. CAD.

gaidāmā Immunoprecise Antibodies peļņa ir -13,10 milj. CAD.

Immunoprecise Antibodies Ltd (IPA) is a leading company in biological research and development of antibodies. IPA's business model is based on the production of customized antibodies and associated services for a wide range of applications in medical research and diagnostics. IPA offers an extensive range of products and services that support the discovery and development of new drugs and therapeutic approaches. This includes customized antibodies, humanization services, antibody engineering, antibody production, antibody stability testing, and immunassay development. The company serves customers from the pharmaceutical industry, academic research institutions, and biotechnology companies worldwide. It provides customized solutions for customer projects by maximizing the potential of antibody research and development through collaboration with the customer and utilizing its ability to produce customized antibodies. IPA has divided its business into various product and service categories. The "Custom Antibody Discovery" division offers customized solutions for antibody discovery and production. The "Antibody Engineering" division offers services for optimizing antibodies for various applications. In the "Antibody Production" division, IPA produces tailor-made antibodies to meet customer needs. The company uses state-of-the-art technologies to produce its high-quality products and services. IPA has extensive experience in the development of monoclonal antibodies and works with a variety of cell lines and expression systems. The company also uses bioinformatics tools and data analysis methods to accelerate antibody development and improve antibody quality. IPA is headquartered in Canada and has subsidiaries in the United States and Europe. The company works closely with customers and partners to ensure that its products and services meet the needs of the scientific and industrial communities. Overall, Immunoprecise Antibodies Ltd's business model offers a wide range of customized products and services that can enhance antibody development and research. The company is divided into multiple divisions and utilizes state-of-the-art technologies to provide high-quality antibody products. It works closely with customers and partners to develop innovative solutions for biological research and medical diagnostics.

Immunoprecise Antibodies izmaksā dividendes 0 CAD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Immunoprecise Antibodies vai uzņēmums nedod dividendes.

Immunoprecise Antibodies ISIN ir CA45257F2008.

Immunoprecise Antibodies WKN ir A2QJEC.

Immunoprecise Antibodies simbols ir IPA.

Pēdējo 12 mēnešu laikā Immunoprecise Antibodies maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Immunoprecise Antibodies plāno maksāt dividendes 0 CAD apmērā.

Immunoprecise Antibodies pašreizējā dividendu rentabilitāte ir .

Immunoprecise Antibodies maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Immunoprecise Antibodies pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CAD. Tas atbilst dividendes ražībai 0 %.

Immunoprecise Antibodies tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Immunoprecise Antibodies apmērā 0 CAD, kas tika izmaksāta 26.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 26.09.2024..

Pēdējās dividendes izmaksa notika 26.09.2024..

Gadā 2023, Immunoprecise Antibodies izmaksāja 0 CAD dividendes.

Immunoprecise Antibodies dividendes tiek izmaksātas CAD.